MARKET SYNOPSIS
Type-1 diabetes is a chronic condition that requires lifelong medication. The onset of this condition usually occurs in childhood; it also affects obese and aged individuals.
This condition has been directly linked to a sedentary lifestyle, the adoption of which is widespread globally due to various societal, cultural, and economic factors. The rising prevalence of type-1 diabetes is driving the growth of the market.
Strict approvals processes are expected to hamper the growth of this market. However, this may be offset by the growing number of cases per year and increased government assistance for the management of the condition.
The Global Type-1 Diabetes Treatment Market Size is projected to grow from USD 5.6 Billion in 2018 to USD 9.6 Billion by 2025, registering a CAGR of 7.9%.
MARKET USP
The enhanced efficacy of rapid-acting insulin and rising number of specialty treatment centers for type-1 diabetes are aggressively driving the growth of the market.
SEGMENTATION
By Product
• Rapid-Acting Insulin: The rapid-acting insulin segment is expected to be the largest and fastest-growing during the review period. Usually taken before the ingestion of food or drink, rapid-action insulin is easy to introduce into the bloodstream and starts acting within 15 minutes of injection. The segment has been further classified as Admelog, Humalog, Novolog, and others.
• Short-Acting Insulin: Also known as regular insulin, it is included in the World Health Organization’s list of essential medicines.
• Medium-Acting Insulin: This growth of this segment is directly proportional to the growth of the short-acting insulin segment as these insulin types are usually taken concurrently.
• Long-Acting Insulin: This is a growing segment as this type of insulin does not have a peak performance time and is equally effective for the entire duration. It is preferred by healthcare agencies due to its low side effects and gradual action. The segment has been further categorized as Lantus, Levemir, and others.
• Others: Ultra long-term insulin and other experimental insulins are covered in this niche market segment. Though currently the smallest segment, it shows tremendous growth potential due to the numerous beneficial effects and limited side effects of these types of insulin. However, the growth of the segment is limited by stringent regulations, a rigorous testing process, and high costs.
https://www.marketresearchfuture.com/reports/type-1-diabetes-treatment-market-8199